CJC-1295 and ipamorelin work via the growth hormone axis, not the testosterone-producing pathway. There are legitimate human studies showing these peptides elevate growth hormone and IGF-1 in adult participants, who in the main studies happened to be men. However, there is no dedicated study isolating results specific to male physiology, testosterone interactions, or athletic performance for either compound.
Benefits of CJC-1295 and Ipamorelin for men
It is worth clarifying something immediately that is often lost in the way this topic is searched. The main human pharmacological studies for CJC-1295 did indeed recruit adult male and female volunteers together. The primary ipamorelin studies were also conducted specifically in men, in several instances. Neither of these studies, however, were designed to isolate or report findings as specific to male physiology. Available hormonal data pertains to the study population generally, not dedicated „for men” discoveries [1], [2]. In the main CJC-1295 study, healthy adults aged 21–61 years received single escalating doses and multiple dosing regimens. Researchers observed a dose-dependent increase in growth hormone persisting for six days or longer and elevations in IGF-1 persisting for nine to eleven days after a single injection [1]. The original human pharmacokinetic study for ipamorelin specifically used male volunteers. It demonstrated a short, acute pulse of growth hormone peaking around 40 minutes after administration, with a two-hour half-life [2]. A separate study measuring pulsatile growth hormone release after CJC-1295 was also conducted specifically in men, aged 20–40 years [3].
So while there is genuine human hormonal data covering men, framing this as „CJC-1295 and Ipamorelin benefits for men” specifically overstates what those studies were designed to show. None of them compared outcomes between men and women, or reported sex-specific results. As discussed in earlier articles in this series, there are essentially no equivalent studies covering women at all. This means the available data reflects general adult human physiology, not a male-specific benefit profile.
CJC-1295 and Ipamorelin and testosterone in men
Growth hormone and testosterone operate through separate hormonal control systems within the body. There is a growth hormone axis, which CJC-1295 and ipamorelin act upon. And there is the hypothalamic-pituitary-gonadal axis, which manages testosterone production. No human studies identified in this research series have measured testosterone levels in men following administration of CJC-1295 or ipamorelin. A review analysing growth hormone boosters as a potential complementary approach in hypogonadal males – men with clinically low testosterone – explored how these compounds might support body composition and certain symptoms associated with low testosterone, as an adjunct to standard testosterone replacement therapy. However, the proposed benefit was described as an indirect metabolic effect, rather than a direct increase in testosterone itself. The authors of the review were explicit that clinical data supporting this particular application remain limited [4].
Regarding the idea of combining these peptides with testosterone replacement therapy (TRT), no dedicated clinical trials have tested this combination. Therefore, questions about the effects of interactions, safety, or additional benefit when used alongside TRT cannot be answered with direct evidence. The review discussed above raises this as a conceptual possibility worthy of further investigation – an unvalidated protocol [4].
The basic research into ipamorelin is also worth noting here. It has been specifically shown not to significantly raise cortisol or ACTH, the stress hormone pathway. This differentiates it from some older growth hormone-releasing peptides. The same study did not, however, measure or report on testosterone [5].
Taking all this into consideration, describing CJC-1295 or ipamorelin as boosting testosterone in men, or as a validated protocol for supplementing TRT, goes beyond what current evidence supports.
CJC-1295 and ipamorelin for men's athletic performance
Claims regarding athletic performance, strength, muscle growth, or bodybuilding benefits specifically in men are almost entirely based on the general physiology of growth hormone and IGF-1, rather than direct performance outcome research. This aligns with what was discussed in earlier articles in this series concerning muscle growth and fat loss. The most directly relevant supporting data remains a single animal study. A 2026 review in the American Journal of Sports Medicine noted that CJC-1295 combined with ipamorelin significantly improved maximal muscle tension in a mouse model of steroid-induced muscle loss. However, this finding is clearly limited to animal research. It has not been replicated in human studies, let alone one that specifically measured outcomes in male athletes [6].
Broader reviews of the application of injectable peptides in sports medicine have grouped CJC-1295 and ipamorelin among growth hormone axis compounds that remain investigational. These reviews clearly note that clinical evidence supporting their use for athletic performance or muscle growth in humans, whether male or female, is insufficient. They also note that unregulated use in sporting and bodybuilding populations carries additional risks associated with inconsistent product quality [6], [7].
Regarding fat burning specifically, the only clinical trial designed to test the related outcome, visceral fat reduction, was not completed, as discussed in earlier articles in this series. No data specific to male body composition outcomes exist separately from this unfinished study [1].
Taking this into account, any claims describing CJC-1295 and ipamorelin as providing proven strength, muscle, or performance benefits specifically for men should be understood as theoretical extrapolations from hormonal physiology and limited animal data—not demonstrated human trial outcomes.
Limitations of current evidence
Human studies on CJC-1295 and ipamorelin do indeed include male participants. In some instances, such as pharmacokinetic studies and ipamorelin pulsatility studies, they have been conducted exclusively on men. However, none of these studies were designed to isolate male-specific outcomes, compare results by sex, or measure testosterone, athletic performance, or bodybuilding-relevant endpoints.
Claims about TRT linkage protocols, testosterone boosts, or male-specific performance benefits go far beyond what available research has actually measured.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. CJC-1295 and ipamorelin remain research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. No published human studies have measured testosterone levels, athletic performance outcomes, or male-specific effects for either compound. Any individual considering testosterone replacement therapy or performance-related treatment should consult with a qualified healthcare professional for evidence-based options.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[3] Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogue. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[4] Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: The role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl. 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
[5] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[6] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[7] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1